Literature DB >> 16627542

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.

L H Calabrese1, N N Zein, D Vassilopoulos.   

Abstract

Understanding of the natural history and basic biology of hepatitis B virus (HBV) has increased greatly in recent years. In view of this, the following are reviewed here: (a) recent advances in HBV biology pertinent to the rheumatic disease population; (b) the risks of HBV reactivation in patients with rheumatic disease undergoing immunosuppression; and (c) potential strategies to manage these risks.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16627542      PMCID： PMC1798254          DOI： 10.1136/ard.2005.043257

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  53 in total

1.  Chronic hepatitis B.

Authors:  A S Lok; B J McMahon
Journal:  Hepatology       Date:  2001-12       Impact factor: 17.425

2.  Guidelines for the management of rheumatoid arthritis: 2002 Update.

Authors: 
Journal:  Arthritis Rheum       Date:  2002-02

3.  Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis.

Authors:  W Yeo; P K Chan; H L Chan; F K Mo; P J Johnson
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

Review 4.  Hepatitis B e antigen-negative chronic hepatitis B.

Authors:  S J Hadziyannis; D Vassilopoulos
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

5.  Complex HBV populations with mutations in core promoter, C gene, and pre-S region are associated with development of cirrhosis in long-term renal transplant recipients.

Authors:  Petra Preikschat; Stephan Günther; Simone Reinhold; Hans Will; Klemenz Budde; Hans H Neumayer; Detlev H Krüger; Helga Meisel
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

Review 6.  Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease.

Authors:  R P Perrillo
Journal:  Gastroenterology       Date:  2001-03       Impact factor: 22.682

Review 7.  A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002.

Authors:  Hugo E Vargas; Forrest S Dodson; Jorge Rakela
Journal:  Liver Transpl       Date:  2002-01       Impact factor: 5.799

8.  Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.

Authors:  S Ito; K Nakazono; A Murasawa; Y Mita; K Hata; N Saito; M Kikuchi; K Yoshida; M Nakano; F Gejyo
Journal:  Arthritis Rheum       Date:  2001-02

9.  Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation.

Authors:  F Silvestri; A Ermacora; A Sperotto; F Patriarca; F Zaja; D Damiani; R Fanin; M Baccarani
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

10.  Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers.

Authors:  G L Bird; H Smith; B Portmann; G J Alexander; R Williams
Journal:  Q J Med       Date:  1989-10
View more
  48 in total

Review 1.  Management of the immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; James Scriven; Suzaan Marais
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

3.  Therapy: Are TNF blockers safe for patients with hepatitis B virus infection?

Authors:  Manuel Ramos-Casals
Journal:  Nat Rev Rheumatol       Date:  2010-11       Impact factor: 20.543

Review 4.  Treatment of chronic inflammatory diseases with biologic agents: opportunities and risks for the elderly.

Authors:  Alejandro Diaz-Borjon; Cornelia M Weyand; Jörg J Goronzy
Journal:  Exp Gerontol       Date:  2006-11-27       Impact factor: 4.032

Review 5.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

6.  [Rare viral infections during immunosuppressive therapy: a "normal" side effect?].

Authors:  T Glück
Journal:  Z Rheumatol       Date:  2011-07       Impact factor: 1.372

Review 7.  Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy.

Authors:  Pilar López-Serrano; Elsa de la Fuente Briongos; Elisa Carrera Alonso; Jose Lázaro Pérez-Calle; Conrado Fernández Rodríguez
Journal:  World J Hepatol       Date:  2015-03-27

8.  Reactivation of hepatitis B: pathogenesis and clinical implications.

Authors:  Anthony Post; Shweta Nagendra
Journal:  Curr Infect Dis Rep       Date:  2009-03       Impact factor: 3.725

9.  Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.

Authors:  Ryuji Koike; Masayoshi Harigai; Tatsuya Atsumi; Koichi Amano; Shinichi Kawai; Kazuyoshi Saito; Tomoyuki Saito; Masahiro Yamamura; Tsukasa Matsubara; Nobuyuki Miyasaka
Journal:  Mod Rheumatol       Date:  2009-07-10       Impact factor: 3.023

Review 10.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.